Get the Stockscreener App
19.53
0.41%
0.08
Pre-market:
19.53
Urogen Pharma Ltd stock is traded at $19.53, with a volume of 1.13M.
It is up +0.41% in the last 24 hours and up +0.67% over the past month.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
See More
Previous Close:
$19.45
Open:
$19.4
24h Volume:
1.13M
Relative Volume:
0.44
Market Cap:
$903.54M
Revenue:
$82.71M
Net Income/Loss:
$-102.24M
P/E Ratio:
-5.3215
EPS:
-3.67
Net Cash Flow:
$-76.57M
1W Performance:
+0.15%
1M Performance:
+0.67%
6M Performance:
+106.45%
1Y Performance:
+40.40%
1-Day Range:
$18.82
$20.20
1-Week Range:
$18.75
$20.20
52-Week Range:
$3.42
$21.02
Urogen Pharma Ltd Stock (URGN) Company Profile
Name
Urogen Pharma Ltd
Sector
Industry
Phone
972 9 770 7601
Address
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
19.53 | 899.84M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
401.00 | 100.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.90 | 61.55B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.00 | 58.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
706.41 | 43.59B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.04 | 33.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jun-16-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-22-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-19-25 | Resumed | Ladenburg Thalmann | Buy |
| Aug-22-24 | Initiated | Guggenheim | Buy |
| Feb-08-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-27-22 | Initiated | Berenberg | Buy |
| Apr-16-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | National Securities | Neutral |
| May-30-19 | Initiated | JP Morgan | Neutral |
| May-29-19 | Initiated | Goldman | Neutral |
| Jan-29-19 | Initiated | H.C. Wainwright | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Apr-04-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-02-18 | Initiated | Ladenburg Thalmann | Buy |
| Nov-15-17 | Reiterated | Oppenheimer | Outperform |
| Nov-15-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Urogen Pharma Ltd Stock (URGN) Latest News
Will earnings trigger a reversal in UroGen Pharma Ltd.2025 Market Outlook & Verified Short-Term Trading Plans - Newser
Will breakout in UroGen Pharma Ltd. lead to full recoveryMarket Risk Report & Real-Time Buy Signal Alerts - Newser
Will UroGen Pharma Ltd. benefit from macro trendsWeekly Trading Summary & Community Driven Trade Alerts - Newser
What is UroGen Pharma Ltd. s 5 year growth outlookMarket Risk Report & Technical Confirmation Alerts - خودرو بانک
Will UroGen Pharma Ltd. benefit from rate cutsJuly 2025 Chart Watch & Fast Gaining Stock Reports - خودرو بانک
Heatmap analysis for UroGen Pharma Ltd. and competitorsJuly 2025 Fed Impact & Technical Buy Zone Confirmations - Newser
How cyclical is UroGen Pharma Ltd.’s revenue streamJuly 2025 Levels & Daily Chart Pattern Signal Reports - خودرو بانک
How hedge fund analytics apply to UroGen Pharma Ltd. stock2025 Support & Resistance & Long-Term Safe Return Strategies - Newser
Real time pattern detection on UroGen Pharma Ltd. stockQuarterly Portfolio Report & Low Risk Investment Opportunities - Newser
Is UroGen Pharma Ltd. stock overvalued or fairly pricedQuarterly Portfolio Summary & Low Risk Entry Point Guides - خودرو بانک
Institutional scanner results for UroGen Pharma Ltd.Earnings Growth Summary & Technical Pattern Based Buy Signals - Newser
Does UroGen Pharma Ltd. have declining or rising EPSQuarterly Investment Review & Verified Technical Trade Signals - خودرو بانک
Comparing UroGen Pharma Ltd. in custom built stock radarsQuarterly Profit Report & Long-Term Investment Growth Plans - Newser
How to escape a deep drawdown in UroGen Pharma Ltd.Weekly Investment Recap & Reliable Breakout Forecasts - Newser
How to use Fibonacci retracement on UroGen Pharma Ltd.July 2025 Trends & Risk Controlled Daily Trade Plans - Newser
What is UroGen Pharma Ltd. s P E ratio telling usJuly 2025 Market Mood & Free Technical Confirmation Trade Alerts - خودرو بانک
Historical volatility pattern of UroGen Pharma Ltd. visualizedTrade Volume Summary & Weekly Top Gainers Alerts - Newser
Analyzing drawdowns of UroGen Pharma Ltd. with statistical toolsJuly 2025 Momentum & Daily Profit Focused Screening - Newser
Can UroGen Pharma Ltd. keep up with sector leadersJuly 2025 Retail & Safe Investment Capital Preservation Plans - خودرو بانک
Is Now a Good Time to Reenter UroGen Pharma Ltd. getLinesFromResByArray error: size == 0 - thegnnews.com
Why UroGen Pharma Ltd. stock attracts strong analyst attentionBull Run & Capital Efficient Trading Techniques - Newser
Non Muscle Invasive Bladder Cancer Pipeline Insight Report 2025 | Phase III Clinical TrialsPromising New Drug DevelopmentsResearchAndMarkets.com - FinancialContent
Technical Models Suggest UroGen Pharma Ltd. May Rebound Soon getLinesFromResByArray error: size == 0 - thegnnews.com
UroGen Pharma Ltd. stock prediction for this weekFed Meeting & Safe Capital Allocation Plans - Newser
How to integrate UroGen Pharma Ltd. into portfolio analysis toolsWeekly Trade Report & AI Forecasted Entry and Exit Points - Newser
UroGen Pharma Ltd. stock trend outlook and recovery pathJuly 2025 Drop Watch & Real-Time Volume Analysis - Newser
What recovery options are there for UroGen Pharma Ltd.July 2025 Technicals & Fast Exit and Entry Trade Guides - Newser
UroGen Pharma Ltd. Shows Early Signs of Technical Strength getLinesFromResByArray error: size == 0 - thegnnews.com
Is now a turning point for UroGen Pharma Ltd.July 2025 Intraday Action & Verified Swing Trading Watchlists - Newser
Can momentum traders help lift UroGen Pharma Ltd.2025 Top Gainers & Scalable Portfolio Growth Methods - Newser
Top chart patterns to watch in UroGen Pharma Ltd.Earnings Performance Report & Free Low Drawdown Momentum Trade Ideas - Newser
Is UroGen Pharma Ltd. stock poised for growthPortfolio Gains Report & Verified High Yield Trade Plans - Newser
UroGen Pharma Ltd. Stock Recovery Path — Analyst Breakdown getLinesFromResByArray error: size == 0 - kangso.co.kr
Leading vs lagging indicators on UroGen Pharma Ltd. performance2025 EndofYear Setup & Long Hold Capital Preservation Tips - Newser
Urogen Pharma Ltd Stock (URGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):